ReviewBiomedical reports2025
Exploring the potential of honokiol as a treatment for cardiovascular disease (Review).
Review in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVDs) remain a leading cause of global mortality. As the burden of these diseases continues to rise, the development of innovative therapeutic agents has become increasingly important. Honokiol, a bioactive compound extracted from the bark and leaves of particular Magnolia species, has garnered attention for its wide-ranging pharmacological effects, including anti-inflammatory, antioxidant, and vasodilatory properties. Emerging research suggests that honokiol holds significant promise as a therapeutic agent for managing CVDs. The present review provides a comprehensive overview of the bioactive properties, cardiovascular effects, mechanisms of action, and potential clinical utility of honokiol for the treatment of CVDs. Furthermore, challenges and future directions for the clinical translation of honokiol are discussed at length to provide additional context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.